Repurposing antihypertensive drugs for pain disorders: a drug-target mendelian randomization study

被引:0
|
作者
Du, Kai [1 ]
Li, Ao [1 ]
Zhang, Chen-Yu [1 ]
Li, Shu-Ming [2 ]
Chen, Ping [2 ]
机构
[1] Beijing Univ Chinese Med, Grad Sch, Beijing, Peoples R China
[2] Capital Med Univ, Beijing Hosp Tradit Chinese Med, Dept Pain Med, Beijing, Peoples R China
关键词
antihypertensive drug; hypertension; pain management; drug target mendelian randomization; drug repurposing; GENE-RELATED PEPTIDE; PRETREATMENT; INJECTION; ASSOCIATION; INSTRUMENTS; PROVIDES; ESMOLOL; BIAS;
D O I
10.3389/fphar.2024.1448319
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective Addressing the rising prevalence of pain disorders and limitations of current analgesics, our study explores repurposing antihypertensive drugs for pain management, inspired by the link between hypertension and pain. We leverage a drug-target Mendelian Randomization (MR) approach to explore their dual benefits and establish causal connections.Methods A comprehensive compilation of antihypertensive drug classes was undertaken through British National Formulary, with their target genes identified using the DrugBank database. Relevant single nucleotide polymorphisms (SNPs) associated with these targets were selected from published genomic studies on systolic blood pressure (SBP) as genetic instruments. These SNPs were validated through MR against acute coronary artery disease (CAD) to ensure genes not linked to CAD were excluded from acting as proxies for antihypertensive drugs. An MR analysis of 29 pain-related outcomes was conducted using the FinnGen R10 database employing the selected and validated genetic instruments. We utilized the Inverse Variance Weighted (IVW) method for primary analysis, applying Bonferroni correction to control type I error. IVW's multiplicative random effects (MRE) addressed heterogeneity, and MR-PRESSO managed pleiotropy, ensuring accurate causal inference.Results Our analysis differentiates strong and suggestive evidence in linking antihypertensive drugs to pain disorder risks. Strong evidence was found for adrenergic neuron blockers increasing migraine without aura risk, loop diuretics reducing panniculitis, and vasodilator antihypertensives lowering limb pain risk. Suggestive evidence suggests alpha-adrenoceptor blockers might increase migraine risk, while beta-adrenoceptor blockers could lower radiculopathy risk. Adrenergic neuron blockers also show a potential protective effect against coxarthrosis (hip osteoarthritis) and increased femgenpain risk (pain and other conditions related to female genital organs and menstrual cycle). Additionally, suggestive links were found between vasodilator antihypertensives and reduced radiculopathy risk, and both alpha-adrenoceptor blockers and renin inhibitors possibly decreasing dorsalgianas risk (unspecified dorsalgia). These findings highlight the intricate effects of antihypertensive drugs on pain disorders, underlining the need for further research.Conclusion The findings indicate that antihypertensive medications may exert varied effects on pain management, suggesting a repurposing potential for treating specific pain disorders. The results advocate for further research to confirm these associations and to explore underlying mechanisms, to optimize pain management practices.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Association of antihypertensive drugs with periodontitis: a comprehensive drug-target Mendelian randomization study
    Zhou, Ying
    Sun, Liying
    Hu, Jinyu
    Liu, Xiao
    Ma, Yajie
    QUINTESSENCE INTERNATIONAL, 2024, 55 (10): : 814 - 823
  • [2] Association of antihypertensive drugs with COVID-19 outcomes: a drug-target Mendelian randomization study
    Zhang, Kun
    Gao, Hengxing
    Chen, Mingwei
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [3] Association of antihypertensive drugs with psoriasis: A trans-ancestry and drug-target Mendelian randomization study
    Xu, Xiao
    Wang, Shu-yun
    Wang, Rongyun
    Wu, Lin-yun
    Yan, Min
    Sun, Zhi-ling
    Sun, Qiu-hua
    VASCULAR PHARMACOLOGY, 2024, 154
  • [4] Association of antihypertensive drugs with fracture and bone mineral density: A comprehensive drug-target Mendelian randomization study
    Huang, Xin
    Zhang, Tianxin
    Guo, Ping
    Gong, Weiming
    Zhu, Hengchao
    Zhao, Meng
    Yuan, Zhongshang
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [5] Causal relationship between antihypertensive drugs and Hashimoto's thyroiditis: a drug-target Mendelian randomization study
    Cui, Bing
    Chen, Aqin
    Xu, Chengcheng
    Mao, Chaoming
    Chen, Yuehua
    FRONTIERS IN ENDOCRINOLOGY, 2024, 15
  • [6] Genetic insights into repurposing statins for hyperthyroidism prevention: a drug-target Mendelian randomization study
    Huang, Anqi
    Wu, Xinyi
    Lin, Jiaqi
    Wei, Chiju
    Xu, Wencan
    FRONTIERS IN ENDOCRINOLOGY, 2024, 15
  • [7] Repurposing Antihypertensive Drugs for the Prevention of Glaucoma: A Mendelian Randomization Study
    Liu, Jingjing
    Li, Shuang
    Hu, Yang
    Qiu, Shizheng
    TRANSLATIONAL VISION SCIENCE & TECHNOLOGY, 2022, 11 (10): : 12 - 12
  • [8] Association between antihypertensive drugs and hepatocellular carcinoma: A trans-ancestry and drug-target Mendelian randomization study
    Wang, Zhenqian
    Lu, Jiawen
    Hu, Jingyi
    LIVER INTERNATIONAL, 2023, 43 (06) : 1320 - 1331
  • [9] Antihypertensive Drugs for the Prevention of Atrial Fibrillation: A Drug Target Mendelian Randomization Study
    Geurts, Sven
    Tilly, Martijn J.
    Lu, Zuolin
    Stricker, Bruno H. C.
    Deckers, Jaap W.
    de Groot, Natasja M. S.
    Miller, Clint L.
    Ikram, M. Arfan
    Kavousi, Maryam
    HYPERTENSION, 2024, 81 (08) : 1766 - 1775
  • [10] Association of Antihypertensive Drug Target Genes With Psychiatric Disorders A Mendelian Randomization Study
    Chauquet, Solal
    Zhu, Zhihong
    O'Donovan, Michael C.
    Walters, James T. R.
    Wray, Naomi R.
    Shah, Sonia
    JAMA PSYCHIATRY, 2021, 78 (06) : 623 - 631